Bicara Therapeutics BCAX Business Segments — Total other income
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bicara Therapeutics's business segments — total other income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bicara Therapeutics's business segments — total other income?
- Bicara Therapeutics (BCAX) reported business segments — total other income of $4.08M in Q1 2026.
- How has Bicara Therapeutics's business segments — total other income changed year-over-year?
- Bicara Therapeutics's business segments — total other income decreased by 18.6% year-over-year, from $5.01M to $4.08M.
- What is the long-term trend for Bicara Therapeutics's business segments — total other income?
- Over 2 years (2023 to 2025), Bicara Therapeutics's business segments — total other income has grown at a 21.6% compound annual growth rate (CAGR), from -$12.09M to $17.87M.
- What does business segments — total other income mean?
- This metric aggregates non-operating financial gains or losses, including interest income, foreign exchange impacts, and other miscellaneous financial items. It provides insight into the company's financial management outside of its core pharmaceutical development operations.